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Identity 
Alias: 17p syndrome in myeloïd malignancies 
Note: Recently, we and others reported in ANLL and MDS a strong correlation between 17p deletion (a clonal 
cytogenetic anomaly consisting of a deletion of theshort arm of chromosome 17), and a particular form of 
morphological dysgranulopoiesis, we also found in such cases a strong correlation between 17p deletion and p53 
mutation; these correlations suggest that ANLL and MDS with 17p deletion constitute a new morphological-
cytogenetic-molecular entity, the " 17p syndrome " 
 
17p syndrome R- banding: various rearrangements of chromosomes 5 and/or 7, and 17 - Courtesy Jean-Luc Lai. 
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Clinics and pathology 
Disease 
Acute non lymphocytic leuemia/myelodysplastic 
syndromes (ANLL/MDS), chronic myelogenous 
leukemia (CML) in blast crisis. 
Phenotype/cell stem origin 
Mainly refractory anemia with excess of blasts 
RAEB/RAEB-t in MDS, often M2 or M6 in ANLL / 
multi-lineage involvement. 
Etiology 
About 30% of ANLL and MDS with 17p deletion  
are therapy related; t-ANLL and t-MDS occur after a 
lymphoïd neoplasm or a solid tumor treated by 
chemotherapy with an alkylating agent or after 
essential thrombocytemia or polycythemia vera treated 
by hydroxyurea alone or associated with other drugs. 
Epidemiology 
3 to 4% of ANLL and MDS. 
Mean age > 60 years. 
Sex ratio : about 1M/1F. 
Clinics 
Not specific (consequences of cytopenias infection, 
bleeding, anemia) 
Cytology 
Most cases of ANLL and MDS with 17p deletion have 
a particular form of morphological dysgranulopoiesis, 
combining both nuclear and cytoplasmic abnormalities 
in at least 5% of neutrophils; affected cells have 
reduced size and are mostly mature; nucleus is bi- or 
non-lobulated and chromatin is well- or heavily-
clumped; cytoplasm contains variable number of small 
clear vacuoles and sometimes a reduced number of 







17p syndrome - Courtesy Georges Flandrin. 
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but also eosinophilic and basophilic lineages; such 
abnormalities can be observed both in the bone marrow 
and in the peripheral blood; however, in the latter 
instance, it may be difficult to demonstrate pseudo-
Pelger Huët anomaly, due to frequent neutropenia; 
these nuclear changes mimick those found in the so-
called constitutional Pelger-Huët hypolobulation of
polymorphonuclear leukocytes. 
Dysgranulopoiesis features are frequently associated 





Classical anthracycline-Ara C chemotherapy gives poor 
results; the only possibility of cure appears to be by 
allogeneic stem cell transplantation, but very few 
allografted cases have been reported. 
Evolution 
Worsening of cytopenias, progression to ANLL. 
Prognosis 
Very poor, median survival: 4 months. 
Cytogenetics 
Cytogenetics morphological 
17p deletions result mainly from unbalanced 
translocation between 17p and another chromosome 
and less frequently from monosomy 17, 
isochromosome 17q and partial 17p deletion; 
chromosome 5 is the partner chromosome the most 
frequently involved in the unbalanced translocation, 
other involved chromosomes are mainly chromosomes 
7, 12, 18, 21 and 22. 
Cytogenetics molecular 
The breakpoint on chromosome 17 and the extent of 
the deletion of 17p are variable, but the breakpoint is 
always proximal to the p53 gene; the variable extent of 
17p deletion suggests the presence of tumor suppressor 
gene(s) on 17p, inactivated by the deletion. The p53
gene is a good candidate. 
Additional anomalies 
Chromosome 17p rearrangement or monosomy 17 are 
frequently associated to at least 2 other chromosomal 
rearrangements and are therefore part of complex 
abnormalities; the most frequent additional 
abnormalities include chromosomes 5 and/or 7, but also 
chromosomes 12, 16 and 11; complex karyotypes are 
associated in some cases with unidentified ring or 
marker chromosomes; however, some cases of iso(17q) 













Inactivation of the P53 gene by deletion of one allle 
and mutation of the non deleted allele. 
Detection 
p53 deletion: conventional cytogenetics, FISH with p53 
specific probes. 
p53 mutation: SSCP or immunocytochemistry. 
To be noted 
Note 
In few 17p deletion cases, whole chromosomal painting 
and fluorescence in situ hybridization (FISH) analysis 
with p53 specific probe demonstrate that unidentified 
ring or marker chromosomes observed in conventional 
cytogenetic can contain 17p material including the 
second p53 allele; in these few cases, the particular 
form of morphological dysgranulopoiesis abnormalities 
observed in 17p- syndrome are not observed. 
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